The BSD-500 Hyperthermia System is approved by the FDA to deliver therapeutic heat (hyperthermia) to certain surface or subsurface malignant tumors by the use of either external or interstitial application of energy. The BSD-500 is used to treat patients with recurrent breast cancer.

BSD said that the previous studies have demonstrated that hyperthermia in conjunction with radiation improved local tumor control in recurrent breast cancer patients.

The data showed that previously irradiated patients, a patient group with a dismal prognosis, had the greatest increase in complete response from the addition of hyperthermia 68.2% in the hyperthermia arm versus 23.5% in the no hyperthermia arm. There was also an indication of improved survival in the study results.

As a result of the study, the National Cancer Center Network, an association comprising the 30 tumor centers in the world, added hyperthermia treatment to its globally published guidelines on the treatment of recurrent breast cancer.

BSD Medical develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radio frequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems.